A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Inclusion Criteria Patients must have: * Documented HIV seropositivity (by Western blot or other approved confirmatory test) prior to enrollment. * Pseudomembranous oropharyngeal candidiasis. * Fungal stain or KOH consistent with Candida species, confirmed by a positive mycologic culture. * Ability to swallow study medication. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms and conditions are excluded: * Medical condition requiring use of prohibited drugs. * Primary HIV seroconversion-related mucosal candidiasis. * Systemic candidiasis. * All forms of OPC other than pseudomembranous (unless accompanied by pseudomembranous OPC). * Documented or suspected fungal esophagitis in patients with symptoms of esophagitis. * EKG with prolonged QTc interval or clinically-significant abnormalities. Concurrent Medication: Excluded: * Systemic antifungals (IV or oral). * Topical oral antifungals, e.g., Nystatin, Mycelex, etc. * Medications known to interact with azoles and that may lead to life-threatening side effects: * terfenadine, astemizole, cisapride, ebastine, triazolam, midazolam. * Medications known to lower the serum concentration/efficacy of azole antifungals: * rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid, H2 blockers. * Cytokines (except erythropoietin), interferon, or lymphocyte replacement therapy unless patient already taking these agents for at least 30 days prior to enrollment. * Protease inhibitors,…